We are live on ! Find out more
GPCR icon

Structure Therapeutics

160 hedge funds and large institutions have $2.69B invested in Structure Therapeutics in 2024 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 35 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 35

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

16% more capital invested

Capital invested by funds: $2.33B → $2.69B (+$361M)

12% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $18.6M

1.17% more ownership

Funds ownership: 34.64%35.81% (+1.2%)

4% less funds holding

Funds holding: 166160 (-6)

18% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 33

Holders
160
Holders Change
-6
Holders Change %
-3.61%
% of All Funds
2.3%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.1%
New
27
Increased
69
Reduced
35
Closed
33
Calls
$20.8M
Puts
$18.6M
Net Calls
+$2.16M
Net Calls Change
-$26M
Name Holding Trade Value Shares
Change
Change in
Stake
PM
76
Plustick Management
Virginia
$1.98M +$1.74M +45,000 New
PE
77
Point72 Europe
United Kingdom
$1.97M +$1.06M +27,378 +157%
Bank of Montreal
78
Bank of Montreal
Ontario, Canada
$1.94M +$750K +19,408 +72%
ETC
79
Exchange Traded Concepts
Oklahoma
$1.8M +$1.04M +27,019 +192%
YIH
80
Y-Intercept (HK)
Hong Kong
$1.79M +$1.57M +40,706 New
UBS Group
81
UBS Group
Switzerland
$1.72M +$1.3M +33,717 +629%
Jane Street
82
Jane Street
New York
$1.7M -$2.72M -70,318 -64%
SI
83
Sofinnova Investments
California
$1.7M +$1.16M +29,877 +335%
PA
84
Perceptive Advisors
New York
$1.53M
DCM
85
DAFNA Capital Management
California
$1.49M +$1.12M +29,000 +580%
JP Morgan Chase
86
JP Morgan Chase
New York
$1.49M +$986K +25,500 +302%
BFM
87
Boothbay Fund Management
New York
$1.48M +$1.3M +33,663 New
CCM
88
Cinctive Capital Management
New York
$1.41M +$653K +16,883 +111%
Russell Investments Group
89
Russell Investments Group
United Kingdom
$1.39M +$510K +13,196 +71%
HS
90
HighVista Strategies
Massachusetts
$1.39M -$132K -3,410 -10%
GCP
91
GSA Capital Partners
United Kingdom
$1.34M +$1.18M +30,464 New
Nomura Asset Management
92
Nomura Asset Management
Japan
$1.29M +$298K +7,719 +36%
Natixis Advisors
93
Natixis Advisors
Massachusetts
$1.17M +$297K +7,670 +40%
AA
94
AlphaCentric Advisors
Puerto Rico
$1.14M
EGM
95
Engineers Gate Manager
New York
$1.12M -$696K -18,006 -41%
PCM
96
Prelude Capital Management
New York
$1.1M +$966K +24,977 New
SAM
97
Sectoral Asset Management
Quebec, Canada
$1.07M +$427K +11,030 +83%
Simplex Trading
98
Simplex Trading
Illinois
$933K -$622K -16,078 -43%
TC
99
TwinBeech Capital
New York
$924K -$836K -21,613 -51%
MCC
100
Money Concepts Capital
Florida
$886K -$14.7M -380,776 -95%

GPCR Hedge Fund Activity: Q3 2024 in Review

160 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q3 2024, worth a combined $2.69B — up 16% from $2.33B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of GPCR and 27 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 69 added.

The largest buyer was Point72 Asset Management, adding an estimated $33.7M. The largest seller was Adage Capital Partners, cutting an estimated $37.2M.

  • 160 institutional investors held Structure Therapeutics (GPCR) as of Q3 2024, down from 166 in Q2 2024.
  • Funds reported $2.69B of Structure Therapeutics stock for Q3 2024, up 16% quarter-over-quarter.
  • 27 funds opened new Structure Therapeutics positions in Q3 2024 and 33 closed out, a net change of -6 holders.
  • The largest Structure Therapeutics buyer in Q3 2024 was Point72 Asset Management, an estimated $33.7M added.
  • The largest Structure Therapeutics seller in Q3 2024 was Adage Capital Partners, an estimated $37.2M sold.

Based on aggregated 13F filings for Q3 2024.